Prolaris Prostate Cancer Prognostic Test

Enhance your patient’s prostate cancer management

Prolaris® provides the precision needed to tailor treatment strategies for your patients

Precise testing

Tailored results

Empowered decisions

Prostate cancer treatment decisions are hard

Determining whether your prostate cancer patients are safe for active surveillance or would benefit from single- or multimodal treatment can be challenging. Traditional risk assessment methods may not provide the full picture, leading to uncertainty in treatment decisions.

Inform decisions with enhanced prognostic power

Introducing Prolaris®, a prostate cancer prognostic test that combines traditional prognostic factors with an individualized molecular score to stratify patient risk precisely. It adds significant prognostic power to traditional prostate cancer risk assessment methods1, providing you with the confidence to develop the right treatment plan.

Precise testing

Prolaris® provides precise risk stratification by combining PSA & Gleason with an independent gene expression score based on cell cycle proliferation (CCP).

Tailored results

Prolaris® is the only test with validated thresholds for active surveillance2 and multimodal treatment in untreated patients3,4. Assess risk for any patient in any NCCN risk group.2

Empowered decisions

Prolaris® helps you safely prescribe active surveillance or single and multimodal therapy for men who need it, empowering your treatment decisions.

Clarity and confidence in your decisions

With the prognostic power of Prolaris®, trusted by over 5 million patients worldwide, we bring clarity to your prostate cancer treatment decisions. As recommended by national cancer guidelines, Prolaris® provides the confidence needed to navigate treatment decisions effectively.

Recommended by NCCN5 and ASCO6

5 million patients tested

10 clinical validation studies1-4,7-10

How to test with Prolaris®

1. Prescribe Prolaris®

Prolaris® utilizes existing tissue from the diagnostic biopsy. No additional biopsies or blood draws are required. All you need to do is prescribe.

2. Let the lab do the work

Once prescribed, the lab takes over. Using advanced technology, the lab analyzes the biopsy sample to generate a Prolaris® Score.

3. Use the Power of the Result

With the patient’s 10-year disease-specific mortality or metastasis risk, make personalized treatment decisions under conservative or curative interventions.

    See how Prolaris® has helped patients

    The Prolaris® white paper tells the story of consistent data across its range of clinical validation and utility studies.

    Request the white paper to learn how it can provide life-changing insights for your patients.

    Unlocking precision in prostate cancer treatment with Prolaris®

    Upon prescribing Prolaris®, you unlock a powerful tool in personalized prostate cancer treatment.

    The lab analyzes the biopsy sample, generating a Prolaris Score that estimates your patient’s 10-year prostate cancer mortality or metastasis risk according to a conservative or curative approach. This score, visualized on a graph, provides a clear understanding of the patient’s unique risk profile.

    With this knowledge, you can confidently make personalized treatment decisions. This process, trusted by over 5 million patients and recommended by national cancer guidelines, brings precision and confidence to your clinical practice.

    It’s not just about treating prostate cancer – it’s about treating your patient in the best way for them.


    1. Cuzick, J, et al. “Prognostic Value of a Cell Cycle Progression Signature for Prostate Cancer Death in a Conservatively Managed Needle Biopsy Cohort.” British Journal of Cancer, vol. 106, no. 6, 2012, pp. 1095–1099
    2. Lin, Daniel W., et al. “Identification of Men with Low-Risk Biopsy-Confirmed Prostate Cancer as Candidates for Active Surveillance.” Urologic Oncology: Seminars and Original Investigations, vol. 36, no. 6, 2018
    3. Tward JD, et al. “Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer.” Journal of Clinical Oncology. Vol. 38, no. 6, 2020, pp. 346
    4. Tward, Jonathan D., et al. “Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-Cycle Risk (CCR) Score Threshold for Prognosticating Benefit from Multimodality Therapy.” Clinical Genitourinary Cancer, vol. 19, no. 4, 2021
    5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer. Version 2.2023 – July 17 2023. Accessed July 18 at
    6. Eggener, Scott E., et al. “Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.” Journal of Clinical Oncology, vol. 38, no. 13, 2020, pp. 1474–1494
    7. Cuzick, J, S Stone, et al. “Validation of an RNA Cell Cycle Progression Score for Predicting Death from Prostate Cancer in a Conservatively Managed Needle Biopsy Cohort.” British Journal of Cancer, vol. 113, no. 3, 2015, pp. 382–389
    8. Data on file. Feb 2020.
    9. Tward, Jonathan, et al. “The Clinical Cell-Cycle Risk (CCR) Score Is Associated with Metastasis after Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy with Dose-Escalated Radiation.” International Journal of Radiation Oncology*Biology*Physics, vol. 113, no. 1, 2022
    10. Brawer, Michael K., et al. “Development and Validation of a Mutivariate Model Combining Cell Cycle Progression Score with Capra to Predict Prostate Cancer Mortality in a Conservatively Managed Cohort.” Journal of Clinical Oncology, vol. 31, no. 6_suppl, 2013, pp. 67–67